Figure 1.

Schema of cohort of patients with bronchiolitis obliterans syndrome (BOS) as defined by updated National Institutes of Health (NIH) spirometric criteria. All 36 participants in the fluticasone, azithromycin, and montelukast (FAM) trial were included (11). Only patients with clinically recognized BOS from the Fred Hutchinson Cancer Research Center (FHCRC) retrospective cohort were included. Patients from the FHCRC cohort were excluded for factors that would confound analysis of treatment with FAM on FEV₁ trajectory. ICS = inhaled corticosteroid.